The Futility Of Pfizer's Omicron Booster In Two Headlines

Big Pharma Will Never Catch Up To COVID-19

Timing is everything.

Two simple news articles that appeared on the same day tell us everything we need to know that Pfizer's new and improved but still toxic mRNA Omicron booster shot will not be effective in the real world.

Pfizer Is Submitting Its Untested Omicron Booster Shot For FDA Approval

Yesterday (August 22), Pfizer and BioNTech announced submitting a request to the FDA for Emergency Use Authorization (EUA) for its Omicron-specific booster inoculation.

In an announcement, Pfizer-BioNTech requested emergency use authorization for a booster dose of the vaccine, which contains a combination of the genetic material mRNA from the original virus circulating when the vaccine was initially approved in August 2021, and mRNA from the newer BA.4 and BA.5 subvariants. The vaccine is intended for anyone 12 years or older.

The new shot is a “bivalent” preparation that aims at both the original (and largely extinct) SARS-CoV-2 strain as well as the BA.4 and BA.5 subvariants within the Omicron lineage.

Lost in the propaganda is the sobering reality that Pfizer has not actually tested this new mRNA cocktail, and is attempting to leverage earlier test data from discarded mixtures (emphasis mine).

The bivalent vaccine contains mRNA encoding the original SARS-CoV-2 spike protein, which is present in the original Pfizer-BioNTech COVID-19 Vaccine, together with mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant. Pre-clinical data showed a booster dose of Pfizer and BioNTech's Omicron BA.4/BA.5-adapted bivalent vaccine generated a strong neutralizing antibody response against Omicron BA.1, BA.2 and BA.4/BA.5 variants, as well as the original wild-type strain. A clinical study investigating the safety, tolerability and immunogenicity of the Omicron BA.4/BA.5-adapted bivalent vaccine in individuals 12 years of age and older is expected to start this month.

What exactly is “pre-clinical data”? Put simply, this is the data gathered during the “pre-clinical” phase of drug development as outlined within FDA regulations to determine if a proposed new medication can be safely tested in humans.

Usually, preclinical studies are not very large. However, these studies must provide detailed information on dosing and toxicity levels. After preclinical testing, researchers review their findings and decide whether the drug should be tested in people.

The pre-clinical phase does not determine if a medication is actually effective—merely that a reasonably safe clinical trial can be designed to ascertain actual efficacy.

The other day, Igor Chudov outlined how much “quackery” there was surrounding the mRNA inoculation boosters, including how untested the boosters are.

Covid Vaccine Quacks and Charlatans Promoting "Ba.5 Booster"

This morning Pfizer essentially agreed with Igor.

Omicron BA.4 And BA.5 Are About To Be Displaced

Ironically, even if Pfizer had done proper testing of its Omicron “booster” shot, it likely would not have mattered. Already new SARS-CoV-2 variants are circulating and may succeed in displacing BA.4 and BA.5 as the dominant strains of the virus.

Experts in California are closely tracking two newer subvariants, BA.4.6 and BA.2.75 — themselves members of the Omicron family. It isn’t clear whether they will eventually spread to worrisome extents in the state, but there’s reason to pay attention as they’ve caused concern elsewhere in the world.

BA.2.75 has already received some media attention, having surfaced in California last month with a bit of hooplah then that it might become a dominant strain and displace BA.5.

Well, Lookee Here, Yet Another Variant

Since it was first noticed, BA.2.75 has apparently succeeded in displacing BA.5 in India, and is reported to be making inroads against BA.4.6 as well.

Eric Topol @EricTopol

While BA.2.75 is becoming dominant in India, out-competing BA.5, we're now seeing signs it can also compete with BA.4.6 in Australia, as posted by @Mike_Honey_ /2

If the evolutionary patterns observed elsewhere are replicated here in the United States, the BA.5 subvariant’s days as the dominant strain are already numbered, and Pfizer’s BA.5-specific booster will become available just in time to watch BA.5 ride off into the sunset. The booster is not yet here and already it is being rendered obsolete by time and Mother Nature.

Viruses Evolve. That’s What They Do.

Even if there was not already a BA.2.75 strain circulating that was capable of displacing BA.5 as the dominant strain in the US, there soon would be. Evolution does not reach an endpoint and then stop, but is a constant process of change.

All viruses mutate, change, and evolve, but single strand RNA viruses like SARS-CoV-2 (and, incidentally, most infectious respiratory pathogens), tend to evolve quite rapidly

¹

.

RNA viruses are perhaps the most intriguing biological entities in which to study mutation rates. They encode their replication machinery, and thus their mutation rates can be optimized for their fitness (in comparison to small DNA viruses that use the polymerases of their host cells). Their inherently high mutation rates yield offspring that differ by 1–2 mutations each from their parent [9], producing a mutant cloud of descendants that complicates our conception of a genotype’s fitness.

Not even Big Pharma has the power to stop a virus that wants to virus.

No matter what new mRNA inoculations Pfizer produces, no matter which strains Pfizer uses to produce those new mRNA inoculations, Pfizer will forever be two steps behind the evolution of the virus, and it is not possible for them to get ahead of the virus—there is no way for anyone to know which strain will become dominant (and thus which strain will warrant its own booster shot) until that strain does become dominant.

Thus, even if the mRNA inoculations were successful vaccines, even if they were not toxic failures producing appalling numbers of adverse events while not protecting against the SARS-CoV-2 virus, they would still be forever late to the show. The inoculations cannot be developed faster than the virus can evolve, yet new development must wait on that evolution. Pfizer has no way to even catch up to the SARS-CoV-2 virus, and it is both foolish and dangerous for Pfizer to even try.

This is the plain takeaway from the fact that, on the same day Pfizer petitioned the FDA for permission to inject its latest mRNA concoction into people’s arms, the corporate media was already reporting on the “next” dominant strain of the virus that will render that concoction pointless even by the standards of the Pandemic Panic Narrative.

1. Duffy, Siobain. “Why are RNA virus mutation rates so damn high?.” PLoS biology vol. 16,8 e3000003. 13 Aug. 2018, doi:10.1371/journal.pbio.3000003